Penalized Bayesian methods for product ranking using both positive and negative references.

Clement Laloux¹, Bruno Boulanger¹, Philippe Bastien², Bradley P Carlin³, Arnaud Monseur¹, Carole Guillou⁴, Daiane Garcia Mercurio⁴, Hussein Jouni²

¹Data Strategy and Quantitative Sciences, Cencora-PharmaLex Belgium, Mont-Saint-Guibert, Belgium.

²Department of Data Science, L'Oreal Research & Innovation, Clichy, France.

³Data Science and Statistics, PhaseV Trials, Inc, Boston, USA.

⁴Department of Clinical Evaluation, L'Oreal Research and Innovation, Chevilly-Larue, France.

PubMed DOI

Abstract

Product ranking according to pre-specified criteria is essential for developing new technologies, allowing identification of more preferable candidates for further development. Such ranking often builds on the results of a network meta-analysis, where the relative or absolute performances of the various products are synthesized across multiple clinical studies, each of which considered only a subs…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.